{"entity":{"id":"nct05669482","kind":"trial","name":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","aka":["RAMP205"],"tldr":"A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in metastatic cancer, run by Verastem, Inc., active and no longer recruiting.","summary":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05669482 by Verastem, Inc., with 40 participants planned, started 2023-03-22 and due to reach its primary completion in 2026-08-31. Interventions recorded: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel. Conditions listed: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05669482","url":"https://clinicaltrials.gov/study/NCT05669482"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine","paclitaxel"],"companies":["verastem"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05669482","phase":"1/2","setting":"A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas","sponsor":"Verastem, Inc.","participation":[{"nct":"NCT05669482","source":"https://clinicaltrials.gov/study/NCT05669482","fetchedAt":"2026-10-07T16:53:49.617Z","studySha256":"74ca688d0c071a3ce5b317006982a0bfd99061d9a5c1f9e7949ce0f99f7d3116","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-09-02","leadSponsor":"Verastem, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":40,"enrolmentType":"ESTIMATED","siteCount":12,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2023-03-22","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05669482/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"}]}}